Pharma Industry News

EMA confirms path for Diurnal’s Chronocort despite trial failure

The company is on track to submit a Marketing Authorisation Application in the fourth quarter of 2019.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]